2Hicklin DJ,Ellis LM.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J].J Clin Oncol,2005,23(5):1011-1027.
3Miller K,Wang M,Gralow J,et al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J].N Engl J Med,2007,357(26):2666-2676.
4孙燕,周际昌.临床肿瘤内科手册[N].第3版.北京:人民卫生出版社,1996:30-33.
5Traina TA.Bevacizumab in the treatment of metastatic breast cancer[J].Oncology(Williston Park),2009,23 (4):327-332.
6Blowers E,Hall K.Managing adverse events in the use of bevacizumab and chemotherapy[J].Br J Nurs,2009,18 (6):351-356,358.
3Jang S, Ackler J, Braitman L, et al. Depression and quality of Life in cancer patients undergoing chemotherapy: rela-tion between the Zung Self-Rating Depression Scale and Functional Assessment of Cancer Therapy-General[J]. Community Oncol,2012,9(4) : 122-126.
4Zhang JM,Wang P,Yao JX,et al. Music interventions for psychological and physical outcomes in cancer: a system- atic review and Meta-analysis[J]. Support Care Cancer, 2012,20(12) : 3043-3053.
5Luckett T, King MT, Butow PN, et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of Life in cancer clinical research:is- sues, evidence and recommendations[J]. Ann Oncol, 2011,22(10) : 2179-2190.
6Moore DH,Tian C, Monk BJ, et al. Prognostic factors for response to cisptatin-hased chemotherapy in advanced cer- vical carcinoma: a Gynecologic Oncology Group Study[J]. Gynecol Oncol, 2010,116 ( 1 ) : 44-49.
